MedTrace Logo

PREFERENTIAL Study

NCT04563559 · Status: WITHDRAWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL

Last updated 2021-11-17

No results posted yet for this study

Summary

To determine patient preference for the dexamethasone insert or topical prednisolone therapy through at Day 45 as measured by - Modified COMTOL survey.

Conditions

  • Cataract Surgery
  • Glaucoma Surgery

Interventions

DRUG

Dextenza 0.4Mg Ophthalmic Insert

The eye will have a sustained release device of Dexamethasone 0.4 mg placed in the inferior nasal lacrimal system.

DRUG

Prednisolone Acetate 1% Ophthalmic Suspension [PRED FORTE]

The eye will be randomized to receive topical treatment with prednisolone acetate 1% on a tapering dose schedule

Sponsors & Collaborators

  • Ocular Therapeutix, Inc.

    collaborator INDUSTRY

  • Duke University

    lead OTHER

Principal Investigators

  • Leon Herndon, MD · Duke Eye Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-30
Primary Completion
2021-11-30
Completion
2021-11-30
FDA Drug
Yes

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04563559 on ClinicalTrials.gov